In summary, our findings revealed that KCNN4 is an essential identity for remodeling components in the tumor microenvironment (TME), and a robust biomarker for predicting prognosis and immunotherapy response in pan-cancer patients. This evidence concerns the gene KCNN4 and neoplasm.